• Businessman and musician Armando Christian Perez or “Pitbull” discussed the need for the music industry to continue on the path of live streaming concert availability
• Revenue in the global music streaming industry is expected to total $23,053 million in 2021, with the United States contributing the most at $8,669 million
• Friendable Inc. saw a 354% increase in artist sign-ups from December 2020 to January 2021, totaling 1,072 and counting since launching the Fan Pass platform in July 2020
• The average online pay-per-view concert ticket is $27, providing artists with a venue with unlimited seats. The average in-person concert ticket price in 2019 was $96.17. With current restrictions, venues would not be able to facilitate full capacity shows

Friendable (OTC: FDBL), a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications, is uniquely positioned to capitalize on live streaming growth opportunities in the entertainment space, especially in the music sector, through its Fan Pass platform. Since launching in July 2020, the app has gathered a total of 1,072 artist sign-ups and counting. Friendable reported significant growth from December 2020 to January 2021, a 354 percent increase in artist sign-ups (https://ibn.fm/pl17R). The figures are a clear indicator of a growing number of artists adhering to a live streaming and online engagement model to continue connecting with fans and generating revenue in the process, especially during the ongoing pandemic. Musician and businessman Armando Christian Perez, better known by his stage name Pitbull, discussed the live stream music industry during the “Power Lunch” segment in a recent CNBC interview. As a performer, businessman, and philanthropist, Perez shared his insight into the availability of live stream concerts and music platforms for the public, underlining that this approach would give the world what it needs at a very difficult time. “That’s what the world needs, bottom line, right now. They need something. Some kind of escape to take all this negative and negativity out of the way and give them hope and motivation,” Perez said (https://ibn.fm/eiSmA). The musician also discussed collaborating with another live streaming platform which works off a subscription model like Fan Pass. Such platforms are poised to change the way that concerts are handled in the future, even post-pandemic, by offering enhanced accessibility, more cost-effective options and access to a wider potential fan base for artists. Friendable’s Fan Pass platform offers fans the opportunity to watch their favorite artists, speakers, and entertainers on a live stream format. It is free for artists to join the platform. Fan Pass leverages the fans’ monthly subscription fees to generate the revenue shared amongst the channel artists. Additional revenue is generated through the pay-per-view content and artist merchandising. The fan subscriptions for Fan Pass begin at $3.99 per month, with the option to view exclusive pay-per-view content for a one-time fee. The “All Access VIP” option provides fans with access to:

• Special artist interviews
• Live performances and online concerts of their favorite artists
• Live streaming during studio sessions
• One-on-one videos
• Behind-the-scenes photo and video shoots
• Backstage exclusive content – before, during, and after the show
• Streams that highlight the artists’ daily lives

Amidst the global pandemic, Friendable is therefore uniquely positioned to capitalize on growth opportunities within the music and video streaming industries. Revenue within the global music streaming industry is expected to total $23,053 million in 2021 and grow at a CAGR of 9.7%. The projected market volume is anticipated to reach $33,372 million by 2025, with the United States contributing the most revenue, totaling $8,669 million in 2021 (https://ibn.fm/Rs56V). The average pay-per-view concert price has been estimated at $27, which provides fans with the ability to watch the event in the comfort of their home through a compatible smart device (https://ibn.fm/voT7z). For comparison, the average cost of an in-person concert in 2019 was $96.17 (https://ibn.fm/OQtVI). Even when concert venues are reopened and concerts are resumed, maintaining a live stream option will be a smart decision for fans who cannot attend in person or afford to pay this much for a ticket. Friendable and other live streaming music venues are advantageous because they have an unlimited number of seats available versus in-person venues. Even at a reduced ticket price, there is a profit made through the lack of pandemic restrictions alone. In fact, Friendable hopes to make “virtual touring” a permanent part of artists’ schedule. To further promote its Fan Pass platform and increase its popularity among artists and the general public Friendable has secured an exclusive partnership with Brightcove to target the OTT platforms, providing more growth opportunities to the live streaming concert experience. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Global billion-dollar market projected to see steady growth in coming years
• Technological advancements expected to contribute to market growth
• Mediscan software transforms traditional 2D grayscale images into digital 3D high-definition images readily accessible to healthcare providers.

The United States medical imaging market size in 2020 valued at US$134 billion (https://ibn.fm/1oQo2), HYB Holding (OTC: HYBG) is looking to its two-month-old acquisition, Mediscan Inc., to bring significant value to the table. Acquired in November 2020 through a reverse acquisition transaction, Mediscan is a cloud-based software technology used in ultrasound that reconstructs the traditional analog two-dimensional (2D) grayscale visual image into a digital three-dimensional (3D), high-definition quantifiable format. “Major factors driving the [global medical imaging] industry are increasing demand for early-stage diagnosis of chronic disease and rising aging demographics, which is expected to boost the demand for diagnostic imaging across the globe,” stated the Grand View Research report. “Technological advancements, coupled with supportive investments and funds by the government, especially in developing countries, such as India and China, are also expected to contribute to market growth.” Technological advancement is what HYB is bringing to the space. With standard ultrasound 2D greyscale images as the norm and 3D imaging often requiring the use of CT, PET, MRI or X-ray technology, Mediscan’s innovative application could have a measurable impact on the medical imaging industry. The technology is designed to meet the need for imaging equipment and devices that can generate human anatomy data in 3D. Through the Mediscan software, an ultrasound analog 2D grayscale image is transformed into a digital 3D HD format in under a minute. When paired with a portable ultrasound machine, Mediscan has the ability to produce scans that can be read on laptop computers, tablets and even smartphones by on-the-scene medical professionals including primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (“EMS”) personnel, and technicians in isolation wards and emergency rooms. The software requires only an internet connection and can generate 3D medical images of different organs, such as the heart, lungs, tendons, skin and nerves. The impressive growth of the global market for diagnostic imaging creates a promising opportunity for HYB — and for potential investors. HYB is hoping to ride the tide of growth as the company focuses on the growth and development of Mediscan, which already has two patents pending. The innovative software technology is designed to dramatically increase the ability of healthcare providers to use existing ultrasound devices at the point of care to identify meaningful data-driven clinical evaluations of a patient’s condition, whether in long-term, acute or emergency care situations. The software, which integrates with all popular EMR systems, also provides support for treatment options, monitors the patient’s ongoing progress or regress, and documents compliance with required protocols and procedures. For more information, visit the company’s website at www.MyMediScan.com. NOTE TO INVESTORS: The latest news and updates relating to HYBG are available in the company’s newsroom at https://ibn.fm/HYBG

• Austrian researchers report CBD reduces inflammation and speeds recovery in ICU COVID-19 patients
• Research suggests CBD’s anti-inflammatory properties stave off long-term neurological damage associated with COVID-19
• PACR leverages genetic technology to produce potent CBD strains with higher yields per growing season
• Company catalog includes 350 cultivars and 50 super-elite strains prized in industry

CBD may soon become the newest support in the world’s fight against COVID-19: Researchers at the Klagenfurt Clinic in Austria recently reported positive results from cannabidiol (“CBD”) trials on COVID-19 patients that demonstrated reduced inflammation and quicker recovery times (https://ibn.fm/vhsIS). Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF), a Canada-based cannabis company dedicated to producing premium-quality strains and products through a genetics-focused approach, leverages genetic technology to cultivate unique strains prized in the industry for their potency and overall effectiveness.

CBD continues to gain mainstream attention among healthcare professionals and the general public as a way to address symptoms of chronic diseases – particularly those associated with inflammation (https://ibn.fm/FDvS1). Accordingly, researchers at the Klagenfurt Clinic in Austria used CBD oil to treat COVID-19 ICU patients for three weeks and observed positive changes in inflammation markers throughout the treatment.

“We have seen that the inflammation parameters in the blood go down, and people leave the hospital faster than the comparison group,” said Rudolf Likar, head of intensive care medicine at the clinic. “CBD supports the immune system. We’ll probably use this routinely now because it doesn’t have any side effects.”

According to the researchers, CBD’s anti-inflammatory effects surpassed those of other commonly used drugs because of its ability to easily cross the blood-brain barrier and stave off some of the long-term neurological damage associated with the disease.

PACR’s genetics-based approach to cannabis cultivation has produced roughly 350 tested cultivars, including 50 super-elite strains with varying amounts of tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”) – two of over 140 known cannabinoids in the cannabis plant that can produce different effects on the body. The Company also uses genetic technology to optimize its cultivars to produce maximum yields according to varying climatic conditions and growing seasons with the potential to boost profit margins through reduced labor costs and increased output.

A critical competitive advantage that sets PACR apart is its strategic licensing agreement with Phenome One Corp – a privately-held full-service genetics cannabis company that gives PACR access to one of Canada’s largest living genetic cannabis libraries. Along with giving its partners access to a massive database of detailed information, Phenome One also subjects each cultivar to rigorous analysis and testing—a process that goes back more than 30 years.

The growing body of scientific evidence supporting the use of CBD along with increasingly relaxed laws around the use of cannabis is contributing to the ever-increasing market opportunity for cannabis cultivators. PacRoots Cannabis Corp. appears to be favorably positioned to benefit from the explosive growth in demand for their first-in-class high-yield strains that appeal to a wide variety of consumers across the rapidly growing legal cannabis market.

For more information, visit the company’s website at www.PacRoots.ca.

NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Vast opportunities exist in growing cannabis space
• CannAssist is committed to establishing aggressive marketing presence in promising market
• CannAssist brings impressive advancements, achievements to the table, including its propriety CiBiDinol technology

Carefully developing and executing a strategic go-to-market plan has never been more important for companies operating in the cannabis industry, according to a recent “Rolling Stone” article (https://ibn.fm/u7v4y). The article urges cannabis companies to consider the industry from both a competitive perspective as well as an opportunity angle, which is exactly what CannAssist International (OTCQB: CNSC) has done as it looks toward 2021 and a projected $5.8 million share of the market.

“The 2020 election was another exciting turning point: Four new states joined the 12 existing markets with legal recreational cannabis, bringing adult use to 15 regions in just eight short years,” the “Rolling Stone” article reported. “Nearly one in three Americans now live in a state where those aged 21 and older can purchase and possess cannabis freely. This will likely expand significantly with the addition of more East Coast markets poised to legalize in the near future through legislation in New York, Pennsylvania and Connecticut.

“It gets even better,” the article continued. “With a new federal administration comes the likelihood of a mandate to decriminalize cannabis and a path to legalization through bills in Congress such as the passing of the MORE Act by the House of Representatives, with its lead sponsor Vice President Kamala Harris. Consumer sentiment favoring legalization is expanding. According to findings from Pew Research from 2019, two-thirds of Americans approve of adult-use in what has become one of those rare bipartisan issues with differences of opinion occurring predominantly along generational lines.”

CannAssist recognizes the wave of opportunity flooding the cannabis market and is committed to establishing an aggressive marketing presence using tactics across the entire marketing funnel plan as part of its go-to-market strategy (https://ibn.fm/Mrxrn). In part, the company will focus on retail partnership, brand collaborations and influencer programming. In addition, CannAssist is eyeing large-scale video and content capture and will also evaluate avenues for digital advertising, email marketing, and both paid and organic social media engagement.

These efforts are designed to support the company’s efforts to reach its goals in five key product areas: Xceptol Capsules M($1 million), Xceptol Drops ($532,000), Xceptol Pain Cream ($1.27 million), Xceptol Pet product ($130,000), and raw material from its Xceptor Labs ($1.48 million). CannAssist owns Xceptor Labs, which produces and markets the Xceptol brand product line and also produces superior quality raw materials for third-party company use.

A biotechnological pharmaceutical and wellness company, CannAssist brings impressive advancements and achievements to the table—none more notable than its development of CiBiDinol, which simply put is cannabidiol made water compatible (https://ibn.fm/kfpz7). CiBiDinol addresses critical issues regarding CBD molecules, including delivery, bioavailability and short shelf life, by offering predictable potency, reduced dosage requirements and a wider variety of product forms.

Established in May 2017, CannAssist is headquartered in San Diego County, California, and markets its consumer line of cannabidiol (“CBD”) products under the Xceptol brand. CNSC is currently targeting North America, Central America, South America, South Africa, the EU, the UK and the Philippines as viable product markets. The company has established strategic partnerships in sourcing, manufacturing, processing, laboratory, distribution, public relations and legal representation.

For more information, visit the company’s website at www.CannAssistInternational.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC

• Mohawk Group Holdings Inc. designs, develops, markets, and sells consumer products guided by machine learning, natural language processing, and data analytics
• Mohawk is on a mission to become the leading e-commerce consumer brands platform
• The company’s acquisition of Healing Solutions, LLC, itself a leading online seller, heralded Mohawk’s entry into the essential oils sector
• The acquisition is the latest in a string of similar business moves and is expected to increase MWK’s revenue for the 2021 financial year

Mohawk Group Holdings (NASDAQ: MWK), a growing tech-enabled consumer products company, has continued its quest to become the leading e-commerce consumer brands platform with its latest acquisition of Healing Solutions, LLC. MWK paid approximately $15.3 million in cash in addition to issuing approximately 1.4 million shares of Mohawk’s common stock. On its own, MWK has launched consumer products across four brands, spanning home and kitchen, beauty, consumer electronics, and appliances. Thus, the acquisition heralded its entry into the essential oils’ category.

Healing Solutions is a leading online seller of essential oils whose unaudited trailing-twelve-month revenue and operating income (excluding inventory liquidations) as of October 31, 2020, were approximately $65.2 million and $12.7 million, respectively. Notably, MWK paid an amount equivalent to about 3.8 times Healing Solutions’ trailing-twelve-month operating income. This amount excludes additional considerations in the form of shares allocated towards acquiring the e-commerce platform’s inventory. MWK issued 170,000 shares of its common stock for this purpose, subject to adjustments that would not go beyond 280,000 shares.

The acquisition is expected to bump MWK’s revenue upwards, as indicated by Mohawk’s adjusted outlook for the financial year 2021. MWK expects a net revenue ranging between $340 million and $370 million, up from a range of $290 million to $320 million. The Company guided 2021 Adjusted EBITDA to $28 million to $32 million. It also estimates its net income will range between $1 million and $5 million for the period ending December 31, 2021.

Healing Solutions is the latest in a string of acquisitions, which Yaniv Sarig – Mohawk Group Holdings Inc.’s co-founder and chief executive officer – hails as a step forward in the company’s mission to build the leading e-commerce consumer brands platform. “We are thrilled to enter the essential oils category, which further diversifies our e-commerce portfolio of brands. Consumable products with recurring purchases and subscription revenue opportunities that complement our hard goods brands have been on our radar.” Yaniv stated in a news release announcing the acquisition (https://ibn.fm/pYysW).

Yaniv regarded the calculated strategy “to create a supply chain and technology platform designed to operate e-commerce brands across a wide spectrum of categories at scale” as one that was continuing to bear fruit. In late 2020, MWK announced the accretive acquisition of four e-commerce brands, namely Pohl and Schmitt, Spiralizer, Mueller, and Pursteam, adding 43 new products to its portfolio (https://ibn.fm/vzT8w).

Although the CEO claimed that the company was still in the early stages of executing its ambitious goals of becoming a market leader, Mohawk Group Holdings Inc. looks poised to achieve them sooner rather than later.

For more information on Mohawk Group Holdings Inc., visit the company’s website at https://mohawkgp.com/.

In addition, the company has announced a live interview with Mohawk Group Co-Founder & CEO Yaniv Sarig (https://ibn.fm/pz2Vu).

NOTE TO INVESTORS: The latest news and updates relating to MWK are available in the company’s newsroom at https://ibn.fm/MWK

• Frequent, COVID-19 rapid tests could spur end of pandemic, make stay-at-home orders possible
• Countries turning to faster, more affordable tests to curb virus spread, enable economic recovery
• United Medical poised to capitalize on surging demand for rapid testing

Frequent rapid testing could curb COVID-19 within weeks, a recent study published by the University of Colorado Boulder and Harvard University shows (https://ibn.fm/qmy42). Factors such as test turnaround-time and frequency are key in limiting the spread of the virus, making rapid tests one of the key tools for managing the virus outbreak. As such, the rapid tests are increasingly used in countries around the world to enable economic revival and help societies go back to normal. United Medical Equipment Business Solutions Network (“UME”), a company offering both antigen and antibody rapid COVID-19 test kits, stands ready to respond to the growing need for this critical public health tool. The study demonstrates that testing half of the population weekly with inexpensive, rapid-turnaround COVID-19 tests could accelerate virus elimination within weeks. Despite their lower sensitivity compared to gold-standard clinical tests, these rapid kits could enable an approach based on “personalized stay-at-home orders,” which would remove the need for mass closures of hospitality outlets, retail stores and schools, the study notes. For example, in a hypothetical scenario involving a city with 4% of individuals already infected, rapid testing three out of four people every three days would reduce the number ultimately infected by as much as 88%. This would be sufficient to push the epidemic toward extinction within six weeks, authors claim. The research was published against the backdrop of significant commercial and academic effort to develop low-cost, rapid tests that could be deployed in large public settings or commercialized for do-it-yourself use. These tests could enable the comeback of public events, such as sports competitions, concerts and travel, which are currently almost completely shut down because of their high risk of virus spread. Combined with the use of masks, rapid testing of people involved in these activities could bring back to life almost-decimated sectors while minimizing the spread risk at the same time. Several countries have already begun countrywide testing, while the new U.S. administration has named rapid testing as a priority. As the countries are turning to faster, cheaper tests to accelerate the COVID-19 public health response, demand for these products is growing. As a supplier of rapid COVID-19 test kits, United Medical is poised to capitalize on the surging need for rapid testing. Designed to test workers without symptoms as well as those who show certain symptoms or have been in close contact with someone who has been infected, these test kits could be the answer to large-scale testing needs in the future. Capable of quickly and affordably identifying individuals who are most likely to be actively infectious, these products will continue to be a valuable addition to the tool kit in the fight against COVID-19. Testing is most likely to remain an important part of health protocols even after the widespread rollout of the vaccines, securing the sizeable market for rapid testing kits in the future. For more information about United Medical as well as its Medication Management app, visit the www.UnitedMedSolutions.com and www.MedicationManagement.app. NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• UltraPlay provides turn-key platform to reach growing global audience.
• Esports is now a necessity for gambling operators.
• Success in eSports lies in ability to pivot, continually improve player experience, and build brand loyalty.

Mobius Interactive, an online gaming operator, has partnered with the multi award-winning betting provider UltraPlay (https://ibn.fm/dzMDK). This partnership equips Mobius to provide players with access to more than 34 eSports games, live events and mystery jackpots, as well as live and prematch odds. In September 2020, Mobius launched its initial three brands with UltraPlay; this expanded partnership will equip the company to further enhance the player experience in eSports and move forward into new regions worldwide. UltraPlay provides Mobius with cutting-edge technology and a wide range of functionalities. With its focus on sports and eSports betting, live betting, white-label and online casinos, UltraPlay was the natural choice for a turn-key platform to reach an ever-growing global audience. “We are a team of gamers at heart,” said Mobius CEO Lynn Pearce, “so when it came to deciding which eSports iGaming platform provider to partner with when launching our company, it was a no-brainer for us. We knew immediately that we wanted to partner with the multiple esports award-winning UltraPlay.” CEO Mario Ovcharov noted UltraPlay’s excitement for the new partnership as well. “Being [Mobius’s] first-choice iGaming platform provider is great recognition for the entire team of UltraPlay,” Ovcharov said. “What’s even more exciting to us is their enthusiasm and commitment to the eSports betting sector.” According to the Esports Insider, esports is no longer an accessory for gambling operators but rather a necessity (https://ibn.fm/xi1zb). While brick-and-mortar casinos and live sporting events have closed due to social distance restrictions, eSports could pivot to a fully online structure. The global eSports market is expected to reach a value of $3 billion by 2025, following its immense growth in 2020. If current trends hold, 2021 is expected to see a 10% increase in growth. This is largely due to betting operators, such as Mobius, continually improving their products and building brand loyalty (https://ibn.fm/J3Y6D). The partnership between UltraPlay and Mobius is a natural fit, one that will only improve the player experience. The iGaming professionals at UltraPlay combined with the eSports and Casino industry experts at Mobius make it possible to provide a constantly evolving, fully interactive player experience that is customer centric and endlessly entertaining under the Mobius Brand. “We strongly believe that together,” said Ovcharov, “we could further enhance the player experience in a very dynamic sector such as eSports.” Mobius provides players with access to more than 34 eSports games and mega tournaments. Available around the clock, the platform has a wide range of functionalities, mystery jackpots, cutting-edge technology, and live and prematch odds. The company has partnered with UltraPlay, a globally recognized, award-winning, unrivaled eSports odds and platform supplier. The esSports industry is booming, and Mobius is ideally positioned to see the greatest benefit from the boom. For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• The global COVID pandemic, community violence and political strife have all served to batter the national psyche during the past year
• Journalists and researchers have reported rising levels of depression and anxiety as well as a rising number of people experiencing property and violent crime
• Knightscope is a company dedicated to building and marketing autonomous security robots (“ASRs”) as a means of helping to make the United States safer
• Knightscope’s ASR series comes in different models that function from a stationary base or a mobile sentry, serving as a deterrent by 24/7 presence and the technological capability to monitor, record and transmit various data streams
• Mordor Intelligence analysts forecast a favorable market for ASRs, growing at a CAGR of 7.93 percent through 2026 to a $3.91 billion market

Following a year headlined by the impositions of a deadly worldwide pandemic, community violence attributed to racial unrest and national upheaval over political strife, it comes as no surprise that researchers are reporting skyrocketing levels of anxiety and depression and feelings of insecurity in the United States (https://ibn.fm/j4QbO). Home security journalists at SafeWise noted in their second annual State of Safety report last year that 40 percent of respondents throughout the country said they’d had a personal experience with property or violent crime during the previous 12 months, a 73 percent increase over responses in 2019. Broken down between the two categories, there was a 50 percent increase in reports of experiencing violent crime and an 86 percent increase in experiencing property crime (https://ibn.fm/2jfVR). In a virtual fireside interview with IPO Edge recently, security robot innovator Knightscope CEO William Santana Li said his company’s efforts to deploy fleets of autonomous sentries in parks, parking lots and other client perimeters amounts to a personal mission to “make the United States of America the safest country in the world” (https://ibn.fm/XzaeT). In order to accomplish that goal, Knightscope has developed K series autonomous security robots (“ASRs”) that can detect and monitor a variety of information sources, whether that involves facial recognition features, license plate detection, broadcast frequency reception or thermal fluctuation discernment. The ASRs record the information they gather, including streaming video from 360-degree cameras, and can transmit the data to oversight personnel or allow overseers to monitor circumstances live and communicate with people around the robot in real time through the ASRs speakers. “If you just look at the metrics, crime has a trillion-dollar negative economic impact on the U.S. every single year. It’s a hidden tax we all pay in blood, tears and treasure,” Santana Li said. The company’s K1 stationary robot, its mobile indoor K3 model and its outdoor patrolling K5 provide a deterrent to crime simply by being present 24 hours a day, every day of the year, according to Knightscope. The robots can even serve as a safety barrier against the pandemic’s virus transmission, responding to property visitors before human interaction takes place. They also recharge their own batteries at a nearby station when power levels drop significantly, keeping them on the job and economically priced in comparison to potential human staffing costs for the same measure of service. Santana Li noted that self-driving automobiles have received the lion’s share of attention over autonomous robotic technology, but said that in building the company he felt passionately that such endeavors were not the proper way to commercialize the technology, despite his background in the automotive industry. Years after investors began pouring millions of dollars into the automobile applications, real world users are still few and far between because of the need to not only master the technology, but the real world metrics of community safety for vehicles traveling at road speeds. Knightscope’s robots, on the other hand, travel at 1 to 3 mph and serve a specific need for private companies and government clients with little or no threat of erroneously causing harm themselves. “How many people in the audience did a transport or moved something or moved themselves this week in an autonomous vehicle? Nobody, right? So $80 billion went into the sector, nobody shipped anything that’s commercially viable,” Santana Li said. “I believe Knightscope’s the only company in the world operating 24/7, 365 (days) across an entire nation, fully autonomous, no human intervention, with real-world clients and real-world environments.” Knightscope received favorable attention from the market analysts at Mordor Intelligence, who cited the K5’s usefulness as a sign that the industry’s technology is evolving. Mordor forecasts a global market for ASRs reaching $3.91 billion by 2026, indicating it expects such platforms to increase in popularity with a CAGR of 7.93 percent between now and then (https://ibn.fm/KzblF). For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• XPhyto Therapeutics Corp. plans to commercialize its rapid and portable PCR Kit this year to provide point-of-care diagnostics
• The company is confident about the successful validation of the PCR kit for the European commercial (CE-IVD) approval in Q1 2021
• Hugh Rogers, CEO and Director of XPhyto, revealed in the latest news release that the company will make investments and development of psychedelic treatments

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator involved in the development of new pharmaceuticals, diagnostic products, and psychedelic medicine.

As a part of its business strategy for the year 2021, the company plans to commercialize its rapid PCR kit, “the one internationally recognized standard for testing Covid-19.” This announcement was made on January 18, 2021, when the company outlined its business strategy for 2021.

XPhyto’s rapid PCR diagnostic kit, secured through a strategic German alliance with 3a-diagnostics GmbH (“3a”), is a low-cost disposable kit with a turnaround time of fewer than 30 minutes. XPhyto is positive about the successful validation of the PCR kit for the European commercial (CE-IVD) approval in Q1 2021 (https://ibn.fm/cJpDM).

Why is a Rapid Testing Kit critical in controlling the COVID pandemic?

With vaccines rolling out sporadically, a rapid definitive kit could play a pivotal role in 2021 to bring the pandemic under control. PCR kits are reliable and accurate tests for Covid-19 diagnosis.

XPhyto’s quick-turnaround time makes this PCR kit well-suited for mobile and pop-up labs. It is very important as the main hurdle for covid-19 testing is the long turnaround time that ranges from 4 hours to a few weeks.

This innovation is expected to be welcomed by the government and the healthcare providers who struggle with the bottlenecks of difficult diagnostic procedures (https://ibn.fm/Irm4I).

In the same news release, Hugh Rogers, CEO and Director of XPhyto, stated that the company is geared to make continued investments and development in the arena of psychedelic medicine.

As per the statistics from the US Center for Disease Control (“CDC”), 11% of Americans have contemplated suicide since the Covid-19 outbreak. Millions of Americans and Europeans are suffering from anxiety and mental illnesses, especially amidst the coronavirus outbreak. This phenomenon has expedited the development of psychedelic compounds for the formulation of mood-improving therapeutic pharmaceutical drugs (https://ibn.fm/Uk8aW).

Professor Löbenberg, a reputed scientist and director of XPhyto Therapeutics Corp holds Health Canada licenses for research and analytical testing of a wide range of psychedelic compounds, including molecules like LSD, psilocybin, and MDMA.

In addition to Dr. Löbenberg’s drug development experience, XPhyto’s German subsidiary –Vektor Pharma TF GmbH – has globally recognized drug delivery technology and manufacturing capabilities. Prof. Dr. Thomas Beckert, managing director of Vektor Pharma TF GmbH stated that the year 2021 will be pivotal for Vektor as the company will establish itself for commercial manufacturing, pipeline development, and drug formulations for critical mental health conditions (https://ibn.fm/hhgxP).

The market intelligence firm, Data Bridge Market Research, estimated that the psychedelic pharma market could grow to almost US $7bn by 2027 (https://ibn.fm/YF7Md). Another noted Canadian investment bank, Canaccord Genuity, estimates that the budding psychedelic industry will go on to be worth US $100bn. Companies like XPhyto Therapeutics enjoy an early-mover advantage that will give an edge over business opportunities among competitors within this science-driven psychedelic era.

For a full report on XPhyto’s research and innovation for Psychedelic drugs, read the article https://ibn.fm/4WlM0.

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at  https://ibn.fm/XPHYF

• Pure Extract Technologies pursues study into psilocybin active treatments
• Study to extend for 250-day period, targeting a number of milestones
• The study is set to be carried out at Toronto Institute of Pharmaceutical Technology, will be supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregor
• Oregon recently voted to legalize psilocybin mushrooms for therapeutic use, a potential legislative movement which may soon be replicated in other jurisdictions

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, has provided investors with an update in regards to its ongoing study on the formulation and manufacturing of psilocybin-based active treatments through the provision of oral tablets and capsules, as well as a nasal gel which is set to be used as an investigational product (https://ibn.fm/p8GT0).

The study, which is being carried out according to Canadian Good Manufacturing Practice as well as Good Clinical Practice, is set to focus on the formulation, manufacturing and clinical bioavailability testing of rapid onset psilocybin forms – with the latter set to be used in future efficacy clinical trials carried out by both Pure Extracts and its pharmaceutical customers.

The Company has revealed that the research study, which will extend for a 250-day period, will pursue a number of milestones, including:

• Sourcing and procurement of medicinal ingredients, excipients & packaging materials
• Raw Material Testing
• Formulation and Manufacturing Process Development, Stability Testing
• Clinical Batch Manufacturing
• Quality Control Release Testing
• Shipping of Clinical Batches to CRO

The study is scheduled to be carried out at the Toronto Institute of Pharmaceutical Technology (“TIPT”) and is set to be overseen by Dr. Alexander MacGregor, a pharmaceutical science inventor and expert in the field of pharmaceutical technology and novel drug delivery systems. Dr MacGregor has successfully applied for a wide variety of global patents in the field of medical treatments and pharmaceutical drug delivery technologies, with his various innovations resulting in ground-breaking therapeutic drugs for the treatment of cancer, management of diabetes, systemic infections and post-operative pain.

“We are excited about the R&D progress we are going to make with TIPT over the next 6 – 8 months while waiting to receive our Dealer’s License from Health Canada,” commented Pure Extracts’ CEO Ben Nikolaevsky regarding the study and tie-up with the TIPT. “We will be well prepared for our move into the controlled substances world of psychedelics and will have advanced knowledge regarding psilocybin and its associated novel delivery mechanisms.”

While psychedelics continue to be classified as a controlled substance in Canada, officials in the Canadian Government stated in November of 2020 – in response to an earlier petition tabled in Parliament – that there were still avenues whereby certain individuals could gain exemptions to legally consume them.

The group behind the petition, the Canadian Psychedelic Association (https://ibn.fm/fDyBC), said when the petition was originally read before Parliament in September that entheogenic medicines “could be the crucial missing piece in healing epidemic rates of depression, anxiety, PTSD, and drug addiction while empowering people to realize greater wholeness, purpose and connection.”

Nonetheless, the Canadian Government’s statement came only shortly after U.S. voters approved a measure to decriminalize the possession of plant-and fungi-based entheogenic substances, while voters in Oregon went further still – passing a reform initiative seeking to legalize psilocybin mushrooms for therapeutic use (https://ibn.fm/K3mqh).

Through its ongoing study delving into psilocybin based active treatments, Pure Extracts is now seeking to be at the very forefront of the product development curve should Canadian governmental authorities opt to legalize the use of psychedelics and psilocybin mushrooms in the coming future.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL